Literature DB >> 10743502

Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action.

J Saharinen1, M Hyytiäinen, J Taipale, J Keski-Oja.   

Abstract

Growth factors of the transforming growth factor-beta family are potent regulators of the extracellular matrix formation, in addition to their immunomodulatory and regulatory roles for cell growth. TGF-beta s are secreted from cells as latent complexes containing TGF-beta and its propeptide, LAP (latency-associated peptide). In most cells LAP is covalently linked to an additional protein, latent TGF-beta binding protein (LTBP), forming the large latent complex. LTBPs are required for efficient secretion and correct folding of TGF-beta s. The secreted large latent complexes associate covalently with the extracellular matrix via the N-termini of the LTBPs. LTBPs belong to the fibrillin-LTBP family of extracellular matrix proteins, which have a typical repeated domain structure consisting mostly of epidermal growth factor (EGF)-like repeats and characteristic eight cysteine (8-Cys) repeats. Currently four different LTBPs and two fibrillins have been identified. LTBPs contain multiple proteinase sensitive sites, providing means to solubilize the large latent complex from the extracellular matrix structures. LTBPs are now known to exist both as soluble molecules and in association with the extracellular matrix. An important consequence of this is LTBP-mediated deposition and targeting of latent, activatable TGF-beta into extracellular matrices and connective tissues. LTBPs have a dual function, they are required both for the secretion of the small latent TGF-beta complex as well as directing bound latent TGF-beta to extracellular matrix microfibrils. However, it is not known at present whether LTBPs are capable of forming microfibrils independently, or whether they are a part of the fibrillin-containing fibrils. Most LTBPs possess RGD-sequences, which may have a role in their interactions with the cell surface. At least LTBP-1 is chemotactic to smooth muscle cells, and is involved in vascular remodelling. Analyses of the expressed LTBPs have revealed considerable variations throughout the molecules, generated both by alternative splicing and utilization of multiple promoter regions. The significance of this structural diversity is mostly unclear at present.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10743502     DOI: 10.1016/s1359-6101(99)00010-6

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  85 in total

Review 1.  Latent-TGF-beta: an overview.

Authors:  D A Lawrence
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta.

Authors:  J Saharinen; J Keski-Oja
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

3.  Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.

Authors:  Shaoliang Li; Chisei Shimono; Naoko Norioka; Itsuko Nakano; Tetsuo Okubo; Yoshiko Yagi; Maria Hayashi; Yuya Sato; Hitomi Fujisaki; Shunji Hattori; Nobuo Sugiura; Koji Kimata; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

4.  Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage.

Authors:  Christian Schachtrup; Jae K Ryu; Matthew J Helmrick; Eirini Vagena; Dennis K Galanakis; Jay L Degen; Richard U Margolis; Katerina Akassoglou
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

5.  Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Authors:  Gadi Lalazar; Meir Mizrahi; Ilit Turgeman; Tomer Adar; Ami Ben Ya'acov; Yehudit Shabat; Assy Nimer; Nila Hemed; Lidya Zolotarovya; Yoav Lichtenstein; Nadya Lisovoder; Sarit Samira; Itamar Shalit; Ronald Ellis; Yaron Ilan
Journal:  J Clin Immunol       Date:  2015-04-17       Impact factor: 8.317

Review 6.  Marfan's syndrome.

Authors:  Daniel P Judge; Harry C Dietz
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

Review 7.  LTBPs in biology and medicine: LTBP diseases.

Authors:  Daniel B Rifkin; William J Rifkin; Lior Zilberberg
Journal:  Matrix Biol       Date:  2017-12-05       Impact factor: 11.583

8.  Characterization of the renal phenotype in a mouse model of Marfan syndrome.

Authors:  Andrea Hartner; Timo Eifert; Christian S Haas; Cigdem Tuysuz; Karl F Hilgers; Dieter P Reinhardt; Kerstin Amann
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

9.  Arsenic-induced decreases in the vascular matrix.

Authors:  Allison M Hays; R Clark Lantz; Laurel S Rodgers; James J Sollome; Richard R Vaillancourt; Angeline S Andrew; Joshua W Hamilton; Todd D Camenisch
Journal:  Toxicol Pathol       Date:  2008-09-23       Impact factor: 1.902

Review 10.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.